Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.36 |
| ▸ | F13A1 | P00488 | 9/20 | 0.36 |
| ▸ | TGM1 | P22735 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390183 | 0.87 | TGM2 (0.36) | TGM2F13A1TGM1MAPTTGM3 | |
| SCHEMBL2394513 | 0.82 | VEGFA (0.39) | BACE1KRAS | |
| SCHEMBL12259618 | 0.81 | FPR2 (0.41) | TGM2F13A1TGM1MAPTTGM3 | |
| SCHEMBL1725753 | 0.78 | MAPT (0.35) | MAPTKDM4EHSD17B10GAA | |
| SCHEMBL1710652 | 0.77 | FPR2 (0.43) | TGM2F13A1TGM1MAPTTGM3 | |
| SCHEMBL1724433 | 0.74 | KDM4E (0.34) | KDM4E | |
| SCHEMBL2394793 | 0.72 | TGM2 (0.44) | TGM2F13A1TGM1TGM3BACE1 | |
| SCHEMBL1710713 | 0.72 | MAPK8 (0.32) | — | |
| SCHEMBL2394669 | 0.71 | MAPT (0.33) | MAPTKRASUSP30 | |
| SCHEMBL14490213 | 0.70 | TGM2 (0.59) | TGM2F13A1TGM1MAPTTGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | TGM2 1801/4885F13A1 3933/4885TGM1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.